

# Non-coding RNAs and disease: the classical ncRNAs make a comeback

Rogerio Alves de Almeida\*<sup>1</sup>, Marcin G. Fraczek\*<sup>1</sup>, Steven Parker\*<sup>1</sup>, Daniela Delneri\* and Raymond T. O'Keefe\*<sup>2</sup>

\*Faculty of Life Sciences, The University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, U.K.

## Abstract

Many human diseases have been attributed to mutation in the protein coding regions of the human genome. The protein coding portion of the human genome, however, is very small compared with the non-coding portion of the genome. As such, there are a disproportionate number of diseases attributed to the coding compared with the non-coding portion of the genome. It is now clear that the non-coding portion of the genome produces many functional non-coding RNAs and these RNAs are slowly being linked to human diseases. Here we discuss examples where mutation in classical non-coding RNAs have been attributed to human disease and identify the future potential for the non-coding portion of the genome in disease biology.

## Introduction

Eukaryotic genomes are pervasively transcribed producing a plethora of RNA species. These RNAs are essential for many of the important functions in the cell, from the making of proteins to the copying of DNA during cell replication. It is, therefore, not surprising that mutations in RNA can lead to disease. Although much recent attention has been given to the role of newly identified long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in human disease, mutations associated with the more classically defined ncRNAs have also been increasingly recognized as causing disease. These classical ncRNAs are the tRNAs, small nuclear RNAs (snRNAs), telomerase RNA, small nucleolar RNAs (snoRNAs) and the RNA component of RNase mitochondrial RNA processing (MRP) endoribonuclease that have been known to researchers for many years. In the past, it was believed that mutations in any one of these essential classical ncRNAs would more than likely be lethal. Over time it has become apparent that mutations in classical ncRNAs, that partially alter their function, can result in diseases with very specific phenotypes.

Advances in sequencing technologies have made it easier to identify mutations associated with human diseases. But techniques like exome sequencing, which have been extensively exploited to identify disease mutations associated with the protein coding regions of the genome, are not useful for detecting mutations in ncRNA genes. It is usually when

exome sequencing has failed to provide any strong candidate disease associated mutations that researchers then turn to other genetic techniques like linkage analysis to narrow down a genomic region to sequence, or resort to whole genome sequencing. Therefore, mutations associated with the classical ncRNAs have been traditionally slower to identify. The first disease-linked classical ncRNA mutations were found in a mitochondrial tRNA (mt-tRNA) gene associated with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) [1] and the nuclear gene for the RNase MRP RNA associated with CHH (cartilage-hair hypoplasia) [2]. Although more difficult to identify, mutations in classical ncRNAs are now emerging as an increasingly significant class of ncRNA associated with human diseases. In this review we will consolidate what is currently known about disease associated mutations in the classical ncRNAs.

## tRNAs

The tRNAs are present in all living organisms and in human cells they constitute approximately 10% of total RNA [3]. The tRNAs are crucial components of the protein translation machinery, serving as adaptor molecules between the mRNA and the growing chain of amino acids. In the human nuclear genome, at least 597 tRNA genes decoding the standard 20 amino acids have been identified [4], whereas mtDNA encodes 22 unique, single copy tRNAs [5]. Human genetic disorders associated with tRNAs result from either mutations within the tRNA or alteration of the tRNA processing endonucleases, tRNA modifying enzymes and aminoacyl-tRNA synthetases [5]. This section only focuses on the direct link between mutation in tRNA and disease.

For all human disorders associated with mutations in tRNAs, mutations only occur in mt-tRNA [6], as the 22 mt-tRNAs are single copy and are unlikely to be compensated for by other tRNAs. There are over 250 mt-tRNA mutations

**Key words:** ncRNA, RNase mitochondrial RNA processing (MRP), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), telomerase RNA component (TERC), tRNA.

**Abbreviations:** CHH, cartilage-hair hypoplasia; DC, dyskeratosis congenital; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; MERRF, myoclonic epilepsy with ragged red fibres; MOPD1, microcephalic osteodysplastic primordial dwarfism type 1; MRP, mitochondrial RNA processing; mt-tRNA, mitochondrial tRNA; pre-mRNA, pre-messenger RNA; PWS, Prader-Willi syndrome; snoRNA, small nucleolar RNA; SNP, single nucleotide polymorphism; snRNA, small nuclear RNA; snRNP, small nuclear ribonucleoprotein particle; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase.

<sup>1</sup> These authors contributed equally.

<sup>2</sup> To whom correspondence should be addressed (email rokeefe@manchester.ac.uk).

reported to date and catalogued in the MITOMAP database (<http://www.mitomap.org/MITOMAP>; [7]). Most of mt-tRNA mutations appear to influence high energy requiring tissues such as those found in the muscular and nervous systems. Mutations in mt-tRNAs can either be polymorphic or pathogenic and can be located in both the loops and stems of mt-tRNA [8]. Polymorphic neutral mutations are found in all mt-tRNAs, however they usually have no, or little, effect on function or structure of mt-tRNA [9]. Pathogenic mutations have been associated with a wide range of diseases in humans, including myopathy, cardiomyopathy, diabetes, deafness, encephalopathy, epilepsy or other neurological disorders [8,10]. Point mutations in mt-tRNA affect their 3D structure, stability, folding, aminoacylation and can also influence mitochondrial protein synthesis itself [11]. The effects of mutations can lead to cellular respiration defects or decrease in activity of the respiratory chain complexes. The most deleterious effects on the function of mt-tRNAs have point mutations in the anticodon bases. However, only a handful of known mutations occur in such critical positions as they are likely to be lethal [10]. One example of such an anticodon mutation was described in a patient suffering from mitochondrial myopathy, where a nucleotide within the mt-tRNA<sup>Pro(UGG)</sup> anticodon was substituted to UGA which encodes serine [12]. The mutation was only detectable in patient's muscles and caused severe impairment of mitochondrial protein synthesis and oxidative phosphorylation.

Point mutations that lie outside the mt-tRNA anticodon not only can affect the whole mt-tRNA molecule but can alter the structure of the anticodon and thus change the decoding efficiency of mt-tRNA. Two well-known examples are maternally inherited MELAS and myoclonic epilepsy with ragged red fibres (MERRF). These diseases are usually caused by altered modification of uridine in the wobble position in anticodons of mt-tRNA<sup>Leu(UAA)</sup> and mt-tRNA<sup>Lys(UUU)</sup> respectively [13,14]. Patients with MELAS lack 5-taurinomethyluridine ( $\tau\text{m}^5\text{U}$ ) on mt-tRNA<sup>Leu(UAA)</sup>, resulting in a UUG-codon-specific translation defect, leading to a translational depression of ND6, a component of the respiratory chain complex I and reduction in complex I activity. MERRF patients lack 5-taurinomethyl-2-thiouridine ( $\tau\text{m}^5\text{s}^2\text{U}$ ) on mt-tRNA<sup>Lys(UUU)</sup> which causes translational defects for both cognate codons (AAA and AAG). Such patients show a general defect in mitochondrial translation.

The correlation between mutation in mt-tRNA and disease phenotype is complex. The same mutations can lead to different disease phenotypes, and similar phenotypes can be associated with different mt-tRNA mutations. For example, the MELAS phenotype has been associated with at least ten point mutations within the mt-tRNA<sup>Leu(UAA)</sup> but also with several mutations in other types of mt-tRNA (<http://www.mitomap.org/MITOMAP>). Moreover, the same mutational genotype can produce disease in one family member but other family members with the mutation can have no clinical symptoms. This phenomenon is dependent

on the level of heteroplasmy (the coexistence of mutated and non-mutated mt-tRNA) within the cell, organ or an organism. If all mt-tRNA are mutated (homoplasmy), the mutation effect is enhanced. Since mt-tRNA mutations manifest themselves with phenotypic variation between patients, and their expression and abundance varies between tissues, there is a need for better diagnostic tools to understand the genotype–phenotype relationship. Sequencing and quantification of mt-tRNA present in the affected tissues combined with measurement and analysis of respiratory chain enzymes could lead to better diagnosis of mt-tRNA associated diseases.

## RNase MRP RNA

The RNase MRP is an RNP that contains an RNA component (*RMRP* in humans) that is required for RNase MRP function [15]. The functions of RNase MRP are varied and include processing of RNA primers required for mtDNA replication, pre-rRNA processing and cleavage of mRNA to induce its degradation [16]. Mutations in human *RMRP* have been associated with CHH [2]. CHH is characterized by short-limbed dwarfism, sparse fine hair, immunological defects, gastrointestinal malabsorption, anaemia and predisposition to cancer. The *RMRP* mutations found in CHH are insertions, duplications, deletions and single point mutations found within the *RMRP* sequence and within the promoter of this Pol III transcribed ncRNA [17]. Mutations in *RMRP* have been related to cellular defects in rRNA processing and mRNA cleavage, with these defects relating specifically to the disease phenotypes of bone dysplasia and immune deficiency respectively [17].

Interestingly, *RMRP* has recently been found to be associated with two other distinct RNP complexes that may explain some of the other disease phenotypes. *RMRP* has been found associated with the helicase DDX5, a new regulatory partner of the sterol-responsive nuclear hormone receptor ROR $\gamma$ t that controls transcription for the differentiation of T helper 17 lymphocytes [18]. DDX5 interacts with *RMRP* and together the DDX5–*RMRP* complex induces the assembly of ROR $\gamma$ t complexes on specific genes required for the T helper 17 lymphocyte effector programme. Significantly, introduction of an *RMRP* CHH mutation into mice resulted in reduced expression of ROR $\gamma$ t-dependent genes. Therefore, the defective T-cell-dependent immunity seen in CHH may be linked to compromised activity of *RMRP* at ROR $\gamma$ t-dependent genes.

*RMRP* has also been found associated with the telomerase reverse transcriptase (TERT) [19]. TAP-tagged TERT is able to pull down *RMRP* indicating that TERT–*RMRP* form a novel complex distinct from the TERT–TERC telomerase RNP. Together, the TERT–*RMRP* complex has RNA-dependent RNA polymerase activity that produces double stranded RNA that are precursors for production of *RMRP*-specific siRNAs. Mutations in *RMRP* associated with CHH may, therefore, have two effects, first *RMRP* mutations may disrupt the function of the TERT–*RMRP* complex and

second RMRP mutations may change the specificity of any siRNAs derived from *RMRP* [20].

## snRNAs

Splicing of pre-messenger RNAs (pre-mRNAs) is an essential process that is mediated by a ribonucleoprotein complex called the spliceosome. The spliceosome consists of five snRNAs that are associated with proteins forming small nuclear ribonucleoprotein particles (snRNPs) [21]. During splicing, introns are removed and exons are joined together to form a mature mRNA that will later be translated into proteins by the ribosome. In mammals, there are two types of spliceosomes, the major and minor, and they differ in their composition. The major spliceosome consists of U1, U2, U4, U5 and U6 snRNPs, and the minor spliceosome consists of U11, U12, U4atac, U5 and U6atac snRNPs [22]. Only the U5 snRNP is shared by both spliceosomes [22]. The major spliceosome is responsible for removing >99% of human introns, whereas the minor spliceosome is responsible for removing approximately 700–800 introns. Mutations in the RNAs and/or proteins of the spliceosome disturb the normal level of splicing and in some cases, lead to diseases [23–25]. Examples, where mutations in the snRNAs cause diseases are discussed below.

Mutations in the single copy U4atac snRNA have been linked to patients with brain and bone malformations and unexplained postnatal death called microcephalic osteodysplastic primordial dwarfism type 1 (MOPD1), also known as Taybi–Linder syndrome [26]. To date, nine mutations associated with MOPD1 have been described, six of the MOPD1 mutations are located in the 5' stem-loop of the U4atac snRNA, a binding site for the spliceosomal protein 15.5K [27]. The 15.5K protein creates a platform for binding of another protein, PRPF31, that in turn interacts with PPIH/PRPF3/PRPF4 to form the U4atac/U6atac.U5 tri-snRNP complex [27]. Mutations in the U4atac snRNA decrease the formation of the U4atac/U6atac.U5 tri-snRNP complex leading to a small splicing defect and retention of introns that are usually removed by the minor spliceosome [26,27]. Although the splicing defect is small, MOPD1 is very severe resulting in death in the first 3 years of life [26]. The other disease mutations are located in different regions of the U4atac snRNA, one adjacent to the Sm protein-binding site, one in the 3' stem-loop and one in the 3' end of stem I extending this helix by one base pair [27].

Mutation in U4atac causes another congenital disorder named Roifman syndrome. Roifman syndrome differs from MOPD1 and consists of growth retardation, the inability to produce certain antibodies, retinal dystrophy, spondyloepiphyseal dysplasia, cognitive delay and facial dysmorphism [28]. Six individuals from four unrelated families with Roifman syndrome were found to be compound heterozygous, with one U4atac variant overlapping an MOPD1 mutation in the 5' stem-loop, whereas other variants occurred in the stem II or the Sm protein-binding site of the U4atac snRNA [28]. Mutation in the stem II may affect

binding of the PPIH/PRPF3/PRPF4 protein complex [27] and mutation in the Sm protein-binding site may interfere with snRNP assembly and snRNP import into the nucleus [28].

Mutation in the U2 snRNA gene leads to disruption of alternative splicing and neurodegeneration [29]. Mutation in one of the mouse multicopy U2 snRNA genes, *Rnu2-8*, causes ataxia and neurodegeneration through dysregulation of pre-mRNA splicing [29]. This U2 mutation is a five nucleotide deletion in U2 located in the U2/U6 Helix Ia linker which is found between U2 and U6 Helix I and the branch site U2 duplex [29]. This five nucleotide deletion removes two nucleotides of the branch site recognition sequence, an important sequence required for spliceosome assembly and the first catalytic step of splicing.

Since intron retention by the minor spliceosome in mammalian cells is higher compared with the major spliceosome [30] any disruption that causes minor splicing to be even less efficient may have a more dramatic effect compared with a similar situation with the major spliceosome. Replacing a minor intron with a major one with identical context gives up to 8-fold increase in protein yield demonstrating that the minor spliceosome is not only slower but splices minor introns less efficiently [31,32].


The minor spliceosome has been less studied compared with the major spliceosome, but now it is known that mutations in the minor spliceosome can have drastic consequences that, in some cases, are incompatible with life. Mutations leading to severe diseases in other snRNAs are yet to be discovered and may be complicated by many of the snRNAs existing as multiple functional copies.

## snoRNAs

Based on their structure, snoRNAs fall into two classes; box C/D snoRNAs and box H/ACA snoRNAs. Box C/D snoRNAs and box H/ACA snoRNAs guide 2'-O-methylation and pseudouridylation of their nucleotide targets respectively. SnoRNAs are mainly responsible for post-transcriptional modification of rRNAs [33]. Prader–Willi syndrome (PWS) is probably the best understood example of a disease involving snoRNA mutation. PWS is the result of the complete loss of the paternally inherited region 15q11–q13 of chromosome 15 [34]. This region contains 47 and 28 tandem repeats of the box C/D snoRNAs called *SNORD115* and *SNORD116* respectively [35]. Unlike the majority of snoRNAs, *SNORD115* and *SNORD116* are not involved in modification of rRNAs or snRNAs [36]. Using a genome wide array, *SNORD116* has been shown to regulate the transcription of roughly 200 genes [37]. *SNORD115* has complementarity with the serotonin (5-hydroxytryptamine) receptor 5-HT<sub>2C</sub>R transcript and is involved in alternative splicing of the 5-HT<sub>2C</sub>R pre-mRNA [36]. Using mouse models, deletion of the *SNORD115* repeats has a significant impact on the ability of *SNORD116* to control gene expression suggesting that PWS therapies should target both snoRNAs [37].

**Figure 1 | Human diseases associated with classical ncRNAs**

Mutations in both the nuclear DNA and mtDNA that encode classical ncRNAs have been found to cause a number of human diseases. The diseases are listed along with the genes (in brackets) where mutations are found and have been described in this review. RNA secondary structures presented are not completely accurate representations of the specific ncRNAs.



There are known mutations in genes coding for proteins associated with snoRNAs that lead to disease. One example is the *DKC1* gene encoding for dyskerin that is associated with X-linked dyskeratosis congenita (DC) [38]. Analysis of the expression levels of 27 H/ACA snoRNAs in X-linked DC patients revealed significant variation between these snoRNAs [39]. It is possible that differential expression of H/ACA snoRNAs in X-linked DC is responsible for the wide variety of symptoms observed between sufferers. It would be useful to expand on this work in the future, to see if certain snoRNA expression patterns correlate with specific symptoms. However, these studies demonstrate the possible involvement of snoRNAs in human diseases.

Analysis of the human genome has shown that roughly 40% of snoRNAs contain at least one single nucleotide polymorphism (SNP) with 298 SNPs found to be located across 151 snoRNAs [40]. By using the SNPfold algorithm, it was shown that the SNPs in six of these snoRNAs could have a significant effect on RNA secondary structure [40]. This study indicates the potential for snoRNA mutations to cause disease, especially if a snoRNA is involved in the regulation of a critical cellular pathway.

A study of prostate cancer cell lines showed a two base-pair deletion in the box C/D snoRNA *U50* [41]. The same two base-pair deletion in *U50* was found in a similar study using breast cancer cell lines [42]. Based on these results, it is suggested that snoRNA *U50* is linked to the development of

cancer. Although only a few snoRNAs have been associated with human disease to date, as disease gene identification moves away from the exome, we are likely to see more examples of snoRNA mutations being implicated in human disease in the future.

### Telomerase RNA

The RNP complex telomerase, a specialized DNA polymerase that maintains chromosome ends, is composed at its core of the TERT and the telomerase RNA component ncRNA (TERC or hTR) that acts as a template for telomere repeat addition to chromosome ends [43]. Mutations in the single copy ncRNA TERC have been associated with DC, idiopathic pulmonary fibrosis, aplastic anaemia, myelodysplastic syndrome and liver disease [44]. TERC contains three major functional and structural domains which include (1) a TERT binding core domain that forms a pseudoknot and a loop that contains the telomere template sequence, (2) the CR4/CR5 domain which also interacts with TERT and (3) a CR7 domain (or scaRNA domain) that contains the H/ACA motif and binds the H/ACA RNP proteins that includes dyskerin [45]. Disease associated mutations occur throughout TERC and comprise either single nucleotide changes or small to large deletions. These TERC mutations compromise telomerase function causing shortening of telomeres which triggers a DNA damage

response leading to apoptosis or cellular senescence [46–48]. Three mechanisms have been proposed to explain the varied phenotypes associated with TERC mutation [44]. First, in proliferating tissues stem cells lose their potential to provide new cells, second, in tissues with slower turnover additional mutations to those in TERC are required to induce disease associated tissue changes and third, cell senescence causes changes in cellular function (i.e. gene expression) without tissue disruption.

## Conclusions

In this minireview, the known human diseases associated with the classical ncRNAs have been described (Figure 1). As the non-coding genome is significantly larger than the protein coding portion of the genome, there is great potential for the identification of further diseases associated with the classical ncRNAs and other ncRNAs. The development of sequencing techniques targeted to ncRNAs, akin to exome sequencing, would be useful in probing the non-coding portion of the genome when exome sequencing has failed to identify any meaningful disease mutations. In addition, although disease associated mutations in classical ncRNAs have been identified, in many cases the molecular mechanisms of how these disease mutations result in a tissue and/or developmentally specific disease phenotype are still lacking. Uncovering the molecular mechanisms behind how classical ncRNA mutations cause diseases will be key to developing treatments but will also surely provide new information on the functions of these essential ncRNAs.

## Acknowledgements

Due to space limitations we apologize to authors whose relevant primary publications were not cited

## Funding

This work was supported by the Wellcome Trust [grant number 104981].

## References

- Kobayashi, Y., Momoi, M.Y., Tominaga, K., Momoi, T., Nihei, K., Yanagisawa, M., Kagawa, Y. and Ohta, S. (1990) A point mutation in the mitochondrial transfer Rnaleu(Uur) gene in Melas (mitochondrial myopathy, encephalopathy, lactic-acidosis and stroke-like episodes). *Biochem. Biophys. Res. Commun.* **173**, 816–822 [CrossRef PubMed](#)
- Ridanpaa, M., van Eenennaam, H., Pelin, K., Chadwick, R., Johnson, C., Yuan, B., van Venrooij, W., Pruijn, G., Salmela, R., Rockas, S. et al. (2001) Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. *Cell* **104**, 195–203 [CrossRef PubMed](#)
- Goldman, E. (2011) tRNA and the human genome. In eLS, John Wiley & Sons, Ltd, Chichester
- Chan, P.P. and Lowe, T.M. (2009) GtRNAdb: a database of transfer RNA genes detected in genomic sequence. *Nucleic Acids Res.* **37**, D93–D97 [CrossRef PubMed](#)
- Suzuki, T., Nagao, A. and Suzuki, T. (2011) Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases. *Annu. Rev. Genet.* **45**, 299–329 [CrossRef PubMed](#)
- Abbott, J.A., Francklyn, C.S. and Robey-Bond, S.M. (2014) Transfer RNA and human disease. *Front. Genet.* **5**, 158 [CrossRef PubMed](#)
- Lott, M.T., Leipzig, J.N., Derbeneva, O., Xie, H.M., Chalkia, D., Sarmady, M., Procaccio, V. and Wallace, D.C. (2013) mtDNA variation and analysis using mitomap and mitomaster. *Curr. Protoc. Bioinformatics* **44**, 1.23.1–1.23.26
- Florentz, C., Sohm, B., Tryoen-Toth, P., Putz, J. and Sissler, M. (2003) Human mitochondrial tRNAs in health and disease. *Cell. Mol. Life Sci.* **60**, 1356–1375 [CrossRef PubMed](#)
- Florentz, C. and Sissler, M. (2001) Disease-related versus polymorphic mutations in human mitochondrial tRNAs – where is the difference? *EMBO Rep.* **2**, 481–486 [CrossRef PubMed](#)
- Yarham, J.W., Elson, J.L., Blakely, E.L., McFarland, R. and Taylor, R.W. (2010) Mitochondrial tRNA mutations and disease. *Wiley Interdiscip. Rev. RNA* **1**, 304–324 [CrossRef PubMed](#)
- Blakely, E.L., Yarham, J.W., Alston, C.L., Craig, K., Poulton, J., Brierley, C., Park, S.M., Dean, A., Xuereb, J.H., Anderson, K.N. et al. (2013) Pathogenic mitochondrial tRNA point mutations: nine novel mutations affirm their importance as a cause of mitochondrial disease. *Hum. Mutat.* **34**, 1260–1268 [CrossRef PubMed](#)
- Moraes, C.T., Ciacci, F., Bonilla, E., Ionasescu, V., Schon, E.A. and DiMauro, S. (1993) A mitochondrial tRNA anticodon swap associated with a muscle disease. *Nat. Genet.* **4**, 284–288 [CrossRef PubMed](#)
- Ravn, K., Wibrand, F., Hansen, F.J., Horn, N., Rosenberg, T. and Schwartz, M. (2001) An mtDNA mutation, 14453G → A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. *Eur. J. Hum. Genet.* **9**, 805–809 [CrossRef PubMed](#)
- Yasukawa, T., Suzuki, T., Ishii, N., Ohta, S. and Watanabe, K. (2001) Wobble modification defect in tRNA disturbs codon-anticodon interaction in a mitochondrial disease. *EMBO J.* **20**, 4794–4802 [CrossRef PubMed](#)
- Chang, D.D. and Clayton, D.A. (1989) Mouse RNAase MRP RNA is encoded by a nuclear gene and contains a decamer sequence complementary to a conserved region of mitochondrial RNA substrate. *Cell* **56**, 131–139 [CrossRef PubMed](#)
- Esakova, O. and Krasilnikov, A.S. (2010) Of proteins and RNA: the RNase P/MRP family. *RNA* **16**, 1725–1747 [CrossRef PubMed](#)
- Thiel, C.T., Mortier, G., Kaitila, I., Reis, A. and Rauch, A. (2007) Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum. *Am. J. Hum. Genet.* **81**, 519–529 [CrossRef PubMed](#)
- Huang, W., Thomas, B., Flynn, R.A., Gavzy, S.J., Wu, L., Kim, S.V., Hall, J.A., Miraldi, E.R., Ng, C.P., Rigo, F.W. et al. (2015) DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. *Nature* **528**, 517–522 [CrossRef PubMed](#)
- Maida, Y., Yasukawa, M., Furuuchi, M., Lassmann, T., Possemato, R., Okamoto, N., Kasim, V., Hayashizaki, Y., Hahn, W.C. and Masutomi, K. (2009) An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. *Nature* **461**, 230–235 [CrossRef PubMed](#)
- Rogler, L.E., Kosmyna, B., Moskowitz, D., Bebawee, R., Rahimzadeh, J., Kutchko, K., Laederach, A., Notarangelo, L.D., Giliani, S., Bouhassira, E. et al. (2014) Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia. *Hum. Mol. Genet.* **23**, 368–382 [CrossRef PubMed](#)
- Will, C.L. and Luhrmann, R. (2011) Spliceosome structure and function. *Cold Spring Harb. Perspect. Biol.* **3**, a003707 [CrossRef PubMed](#)
- Turunen, J.J., Niemela, E.H., Verma, B. and Frilander, M.J. (2013) The significant other: splicing by the minor spliceosome. *Wiley Interdiscip. Rev. RNA* **4**, 61–76 [CrossRef PubMed](#)
- Crehalet, H., Latour, P., Bonnet, V., Attarian, S., Labauge, P., Bonello, N., Bernard, R., Millat, G., Rousson, R. and Bozon, D. (2010) U1 snRNA mis-binding: a new cause of CMT1B. *Neurogenetics* **11**, 13–19 [CrossRef PubMed](#)
- Hahn, C.N., Venugopal, P., Scott, H.S. and Hiwase, D.K. (2015) Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. *Immunol. Rev.* **263**, 257–278 [CrossRef PubMed](#)
- Wieczorek, D., Newman, W.G., Wieland, T., Berulava, T., Kaffe, M., Falkenstein, D., Beetz, C., Graf, E., Schwarzmayr, T., Douzougou, S. et al. (2014) Compound heterozygosity of low-frequency promoter deletions and rare loss-of-function mutations in TXNL4A causes Burn-McKeown syndrome. *Am. J. Hum. Genet.* **95**, 698–707 [CrossRef PubMed](#)

- 26 Ederly, P., Marcaillou, C., Sahbatou, M., Labalme, A., Chastang, J., Touraine, R., Tubacher, E., Senni, F., Bober, M.B., Nampoothiri, S. et al. (2011) Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. *Science* **332**, 240–243 [CrossRef PubMed](#)
- 27 Jafarifar, F., Dietrich, R.C., Hiznay, J.M. and Padgett, R.A. (2014) Biochemical defects in minor spliceosome function in the developmental disorder MOPD I. *RNA* **20**, 1078–1089 [CrossRef PubMed](#)
- 28 Merico, D., Roifman, M., Braunschweig, U., Yuen, R.K.C., Alexandrova, R., Bates, A., Reid, B., Nalpathamkalam, T., Wang, Z.Z., Thiruvahindrapuram, B. et al. (2015) Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing. *Nat. Commun.* **6**, 8718 [CrossRef PubMed](#)
- 29 Jia, Y.C., Mu, J.C. and Ackerman, S.L. (2012) Mutation of a U2 snRNA gene causes global disruption of alternative splicing and neurodegeneration. *Cell* **148**, 296–308 [CrossRef PubMed](#)
- 30 Niemela, E.H., Oghabian, A., Staals, R.H.J., Greco, D., Puijn, G.J.M. and Frilander, M.J. (2014) Global analysis of the nuclear processing of transcripts with unspliced U12-type introns by the exosome. *Nucleic Acids Res.* **42**, 7358–7369 [CrossRef PubMed](#)
- 31 Niemela, E.H. and Frilander, M.J. (2014) Regulation of gene expression through inefficient splicing of U12-type introns. *RNA Biol.* **11**, 1325–1329 [CrossRef PubMed](#)
- 32 Patel, A.A., McCarthy, M. and Steitz, J.A. (2002) The splicing of U12-type introns can be a rate-limiting step in gene expression. *EMBO J.* **21**, 3804–3815 [CrossRef PubMed](#)
- 33 Lafontaine, D.L.J. (2015) Noncoding RNAs in eukaryotic ribosome biogenesis and function. *Nat. Struct. Mol. Biol.* **22**, 11–19 [CrossRef PubMed](#)
- 34 Falaleeva, M., Sulsona, C.R., Zielke, H.R., Currey, K.M., de la Grange, P., Aslanzadeh, V., Driscoll, D.J. and Stamm, S. (2013) Molecular characterization of a patient presumed to have Prader-Willi syndrome. *Clin. Med. Insights Case Rep.* **6**, 79–86 [PubMed](#)
- 35 Cavaille, J., Buiting, K., Kieffmann, M., Lalande, M., Brannan, C.I., Horsthemke, B., Bachelier, J.P., Brosius, J. and Huttenhofer, A. (2000) Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 14311–14316 [CrossRef PubMed](#)
- 36 Kishore, S. and Stamm, S. (2006) The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. *Science* **311**, 230–232 [CrossRef PubMed](#)
- 37 Falaleeva, M., Surface, J., Shen, M., de la Grange, P. and Stamm, S. (2015) SNORD116 and SNORD115 change expression of multiple genes and modify each other's activity. *Gene* **572**, 266–273 [CrossRef PubMed](#)
- 38 Knight, S.W., Heiss, N.S., Vulliamy, T.J., Greschner, S., Stavrides, G., Pai, G.S., Lestringant, G., Varma, N., Mason, P.J., Dokal, I. and Poustka, A. (1999) X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. *Am. J. Hum. Genet.* **65**, 50–58 [CrossRef PubMed](#)
- 39 Bellodi, C., McMahon, M., Contreras, A., Juliano, D., Kopmar, N., Nakamura, T., Maltby, D., Burlingame, A., Savage, S.A., Shimamura, A. and Ruggero, D. (2013) H/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation. *Cell Rep.* **3**, 1493–1502 [CrossRef PubMed](#)
- 40 Bhartiya, D., Talwar, J., Hasija, Y. and Scaria, V. (2012) Systematic curation and analysis of genomic variations and their potential functional consequences in snoRNA loci. *Hum. Mutat.* **33**, E2367–E2374 [CrossRef PubMed](#)
- 41 Dong, X.Y., Rodriguez, C., Guo, P., Sun, X., Talbot, J.T., Zhou, W., Petros, J., Li, Q., Vessella, R.L., Kibel, A.S. et al. (2008) SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. *Hum. Mol. Genet.* **17**, 1031–1042 [CrossRef PubMed](#)
- 42 Dong, X.Y., Guo, P., Boyd, J., Sun, X., Li, Q., Zhou, W. and Dong, J.T. (2009) Implication of snoRNA U50 in human breast cancer. *J. Genet. Genomics* **36**, 447–454 [CrossRef PubMed](#)
- 43 Collins, K. (2006) The biogenesis and regulation of telomerase holoenzymes. *Nat. Rev. Mol. Cell Biol.* **7**, 484–494 [CrossRef PubMed](#)
- 44 Armanios, M. and Blackburn, E.H. (2012) The telomere syndromes. *Nat. Rev. Genet.* **13**, 693–704 [CrossRef PubMed](#)
- 45 Zhang, Q., Kim, N.K. and Feigon, J. (2011) Architecture of human telomerase RNA. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 20325–20332 [CrossRef PubMed](#)
- 46 Blasco, M.A., Lee, H.W., Hande, M.P., Samper, E., Lansdorf, P.M., DePinho, R.A. and Greider, C.W. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. *Cell* **91**, 25–34 [CrossRef PubMed](#)
- 47 Hemann, M.T., Rudolph, K.L., Strong, M.A., DePinho, R.A., Chin, L. and Greider, C.W. (2001) Telomere dysfunction triggers developmentally regulated germ cell apoptosis. *Mol. Biol. Cell* **12**, 2023–2030 [CrossRef PubMed](#)
- 48 Lee, H.W., Blasco, M.A., Gottlieb, G.J., Horner, J.W., Greider, C.W. and DePinho, R.A. (1998) Essential role of mouse telomerase in highly proliferative organs. *Nature* **392**, 569–574 [CrossRef PubMed](#)

---

Received 1 April 2016  
doi:10.1042/BST20160089